Territory includes: SC, NC, VA, WV, DC, MD, DE
Serving as a field-based extension of Medical Affairs, the Oncology Liaison (OL) will represent the Company and their approved product indicated for the extended adjuvant treatment of adult patients with early state breast cancer.
The OL will build long term peer to peer relationships with opinion leaders, patient treaters and other stakeholders within the breast cancer community to deliver clinical, scientific, and technical education on the role of breast cancer. The OL is responsible for cultivating and maintaining collaborative relationships with influential members of the medical community to support company, disease state and therapeutic awareness, in addition to serving as an advanced technical, scientific, and medical expert for the assigned region. These scientific exchanges will support and/or expand current therapeutic concepts, as well as ensure the safe and effective utilization of Company product(s).
The OL responsibilities include development of KOL customer facing strategy, strategic implementation of KOL relationships based on sound product knowledge, and consistent interactions and feedback with regional and local oncology Key Opinion Leaders (KOLs) across the US within in the defined geography. The primary areas of focus (including but not limited to) are KOL identification and engagement, speaker training and liaising with Medical Affairs (MSLs), Clinical and Early Research and Development, Marketing and Sales.